# Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

> **NCT06342466** · PHASE2 · RECRUITING · sponsor: **Jin Lu, MD** · enrollment: 40 (estimated)

## Conditions studied

- Systemic Amyloidosis

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06342466
- **Lead sponsor:** Jin Lu, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-06
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06342466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06342466, "Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06342466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*